Area of research
Oncology · Cancer Research
Research interest
Research interests include Global Cancer Incidence and Screening, Breast Cancer Treatment Studies, Colorectal Cancer Screening and Detection, and Cancer Risks and Factors.
Trends in Survival and Cure Indicators of Thin and Thick Cutaneous Malignant Melanoma in Italy.
Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial.
Supplementary Table S4 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Data from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Supplementary Figure S3 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Supplementary Figure S2 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Supplementary Figure S1 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Supplementary Table S2 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Supplementary Figure S5 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Supplementary Figure S4 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Supplementary Table S3 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Supplementary Table S1 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Prevalence and indicators of cure of Italian women with vulvar squamous cell carcinoma: A population-based study
Prognostic role of HER2 expression in patients with estrogen receptor positive/HER2-negative breast cancer. Results from a population-based cancer registry study
Abstract PO2-26-01: Prognostic Role of HER2 Expression in Patients with ER-positive/HER2-negative Breast Cancer. Results from a Population-Based Cancer Registry Study
Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study.
Trends in Net Survival from Vulvar Squamous Cell Carcinoma in Italy (1990–2015)
The descriptive epidemiology of melanoma in Italy has changed - for the better
286P Prognostic role of HER2 expression in patients with ER-positive/HER2-negative breast cancer: Results from a population-based cancer registry study
Supplementary Figure 2 from Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease
Supplementary Figure 1 from Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease
Supplementary Figure 1 from Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease
Data from Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease
Preliminary Analysis of the Melanoma Multimedia Educational programme for general practitioners on behalf of the Italian Melanoma Intergroup
Supplementary Figure 2 from Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease
Data from Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease
Supplementary Data 3 from Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease
Supplementary Data 3 from Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease
Evaluation of a training course for general practitioners within the Melanoma Multimedia Education Programme of the Italian Melanoma Intergroup: study protocol
Comparison of cancer risk between neutrophilic dermatoses and plaque psoriasis patients: a cancer registry-based study